Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.69−1.98 (-18.56%)
Close on Nov 17, 2026Market cap $253.10MP/E –Yield –
Enanta Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Enanta Pharmaceuticals's pe ratio was 545.4× on Oct 30, 2020, against 19.8× a year earlier. Over the last 5 years it ranged from 6.3× to 652.4×, with a median of 22.7×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2020 | Oct 30, 2020 | 545.4× | +517.4 |
| 2019 | Dec 31, 2019 | 28.0× | +7.6 |
| 2018 | Dec 31, 2018 | 20.4× | −44.1 |
| 2017 | Dec 29, 2017 | 64.5× | +34.8 |
| 2016 | Dec 30, 2016 | 29.6× | +21.6 |
| 2015 | Dec 31, 2015 | 8.1× | −20.2 |
| 2014 | Dec 31, 2014 | 28.3× | −22.6 |
| 2013 | Dec 31, 2013 | 50.8× | – |
See a number that looks wrong?